Morgan Stanley
CELU icon

Morgan Stanley’s Celularity CELU Stock Holding History

Morgan Stanley’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13 Buy
21
+20
+2,000% +$19 ﹤0.01% 8324
2026
Q1 		$2 Buy
+1
New +$1 ﹤0.01% 8255
2025
Q4 		– Sell
-3,000
Closed -$6.21K – 8245
2025
Q3 		$6.21K Buy
3,000
+2,900
+2,900% +$8.12K ﹤0.01% 7033
2025
Q2 		$196 Buy
100
+50
+100% +$91 ﹤0.01% 7572
2025
Q1 		$87 Hold
50
– – ﹤0.01% 7597
2024
Q4 		$104 Hold
50
– – ﹤0.01% 7461
2024
Q3 		$149 Sell
50
-300
-86% -$884 ﹤0.01% 7403
2024
Q2 		$1.1K Sell
350
-8,500
-96% -$29.5K ﹤0.01% 7142
2024
Q1 		$46.3K Buy
8,850
+3,719
+72% +$15.3K ﹤0.01% 6242
2023
Q4 		$12.7K Sell
5,131
-2,886
-36% -$6.27K ﹤0.01% 6577
2023
Q3 		$17.8K Sell
8,017
-2,432
-23% -$8.74K ﹤0.01% 6522
2023
Q2 		$55.7K Buy
10,449
+4,738
+83% +$30.4K ﹤0.01% 6170
2023
Q1 		$35.4K Sell
5,711
-1,392
-20% -$11.2K ﹤0.01% 6407
2022
Q4 		$91.6K Sell
7,103
-2,891
-29% -$53.3K ﹤0.01% 6013
2022
Q3 		$230K Buy
9,994
+2,327
+30% +$70.6K ﹤0.01% 5665
2022
Q2 		$260K Buy
7,667
+2,679
+54% +$218K ﹤0.01% 5764
2022
Q1 		$435K Sell
4,988
-15
-0.3% -$899 ﹤0.01% 5495
2021
Q4 		$256K Sell
5,003
-97
-2% -$6.2K ﹤0.01% 5931
2021
Q3 		$361K Buy
5,100
+3,960
+347% +$320K ﹤0.01% 5686
2021
Q2 		$116K Sell
1,140
-912
-44% -$92.4K ﹤0.01% 6289
2021
Q1 		$207K Buy
2,052
+386
+23% +$39.6K ﹤0.01% 5642
2020
Q4 		$184K Buy
+1,666
New +$177K ﹤0.01% 5635
2020
Q2 		– Sell
-35
Closed -$3K – 6608
2020
Q1 		$3K Sell
35
-83
-70% -$8.21K ﹤0.01% 6318
2019
Q4 		$12K Buy
+118
New +$11.7K ﹤0.01% 6216

Other funds holding CELU

CVSC
C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BFO
Biltmore Family Office Charlotte, North Carolina $761M AUM 31.91% 1-Year Est. Return

Morgan Stanley's CELU Position: Q2 2026 in Review

Morgan Stanley increased its Celularity (CELU) stake by 2,000% in Q2 2026, buying an estimated $19 and bringing the position to 21 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #8324.

Morgan Stanley first reported a position in CELU in Q4 2019 and has held it in 24 quarters since. The position peaked at $435K in Q1 2022. 39 funds tracked by Wall St. Rank hold CELU as of Q2 2026.

  • Morgan Stanley held 21 shares of Celularity worth $13 as of Q2 2026.
  • Morgan Stanley bought 20 Celularity shares in Q2 2026, an estimated $19.
  • Celularity made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8324 holding.
  • Morgan Stanley first reported a position in Celularity in Q4 2019 and has held it in 24 quarters since.
  • Morgan Stanley's Celularity position peaked at $435K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Celularity as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.